Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension

Histopathology

Volumn 61, Issue 4, 2012, Pages 597-609

  Pogoriler, Jennifer E ^a   Rich, Stuart ^a   Archer, Stephen L ^a   Husain, Aliya N ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Histopathology; Plexiform lesions; Prostaglandins; Vascular remodelling

Indexed keywords

PROSTACYCLIN;

ADULT; ANTICOAGULATION; ARTERIAL WALL THICKNESS; ARTICLE; AUTOPSY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LUNG HEMORRHAGE; MACROPHAGE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; T LYMPHOCYTE; THROMBUS; TREATMENT DURATION; VASCULAR LESION; AGED; HYPERTENSION, PULMONARY; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD;

ADULT; AGED; AUTOPSY; CHILD, PRESCHOOL; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84871928032     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04246.x     Document Type: Article

References (39)

1. Stewart S, Rassl D. Advances in the understanding and classification of pulmonary hypertension. Histopathology 2009; 54; 104-116.
2. Pietra GG, Capron F, Stewart S et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43(12 Suppl. S); 25S-32S.
3. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70; 580-587.
4. Archer SL, Weir EK, Wilkins MR Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010; 121; 2045-2066.
5. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 1996; 334; 296-302.
6. Murata T, Ushikubi F, Matsuoka T et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997; 388; 678-682.
7. Olschewski H, Olschewski A, Rose F et al. Physiologic basis for the treatment of pulmonary hypertension. J. Lab. Clin. Med. 2001; 138; 287-297.
8. Piao L, Fang YH, Cadete VJ et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J. Mol. Med. 2010; 88; 47-60.
9. van Albada ME, Berger RM, Niggebrugge M, van Veghel R, Cromme-Dijkhuis AH, Schoemaker RG. Prostacyclin therapy increases right ventricular capillarisation in a model for flowassociated pulmonary hypertension. Eur. J. Pharmacol. 2006; 549; 107-116.
10. Dammann JF Jr, McEachen JA, Thiompson WM Jr, Smith R, Muller WH Jr. The regression of pulmonary vascular disease after the creation of pulmonary stenosis. J. Thorac. Cardiovasc. Surg. 1961; 42; 722-734.
11. Wagenvoort CA, Wagenvoort N, Draulans-Noe Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J. Thorac. Cardiovasc. Surg. 1984; 87; 876-886.
12. Levy NT, Liapis H, Eisenberg PR, Botney MD, Trulock EP. Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation. J. Heart Lung Transplant. 2001; 20; 381-384.
13. Deb S, Yun J, Burton N, Omron E, Thurber J, Nathan SD. Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. Chest 2006; 130; 214-217.
14. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am. J. Pathol. 1980; 100; 151-178.
15. Hislop A, Reid L. Changes in the pulmonary arteries of the rat during recovery from hypoxia-induced pulmonary hypertension. Br. J. Exp. Pathol. 1977; 58; 653-662.
16. van Albada ME, van Veghel R, Cromme-Dijkhuis AH, Schoemaker RG, Berger RM. Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling. J. Cardiovasc. Pharmacol. 2006; 48; 249-254.
17. Achcar RO, Yung GL, Saffer H, Cool CD, Voelkel NF, Yi ES. Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension. Eur. J. Med. Res. 2006; 11; 203-207.
18. Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010; 138; 1234-1239.
19. Pogoriler JE, Rich S, Gomberg-Maitland M, Archer SL, Husain AN. Effect of prostacyclin treatment on lesions of pulmonary arterial hypertension. Mod. Pathol. 2010; 23; 12A.
20. Jamison BM, Michel RP. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum. Pathol. 1995; 26; 987-993.
21. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum. Pathol. 1997; 28; 434-442.
22. Cool CD, Stewart JS, Werahera P et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am. J. Pathol. 1999; 155; 411-419.
23. Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122; 156-163.
24. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 1994; 144; 275-285.
25. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 2003; 22; 358-363.
26. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest 2006; 130; 182-189.
27. Strassheim D, Riddle SR, Burke DL, Geraci MW, Stenmark KR. Prostacyclin inhibits IFN-gamma-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1- independent manner. J. Immunol 2009; 183; 6981-6988.
28. Hall S, Brogan P, Haworth SG, Klein N. Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 2009; 64; 778-783.
29. Austin ED, Rock MT, Mosse CA et al. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension. Respir. Med. 2010; 104; 454-462.
30. Cella G, Bellotto F, Tona F et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001; 120; 1226-1230.
31. Bozza FA, Shah AM, Weyrich AS, Zimmerman GA. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am. J. Respir. Cell Mol. Biol. 2009; 40; 123-134.
32. Dogne JM, de Leval X, Delarge J, David JL, Masereel B. New trends in thromboxane and prostacyclin modulators. Curr. Med. Chem. 2000; 7; 609-628.
33. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96; 2782-2784.
34. Bogaard HJ, Natarajan R, Henderson SC et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009; 120; 1951-1960.
35. Overbeek MJ, Vonk MC, Boonstra A et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur. Respir. J. 2009; 34; 371-379.
36. Yi ES, Kim H, Ahn H et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am. J. Respir. Crit. Care Med. 2000; 1; 1577-1586.
37. Pietra GG, Edwards WD, Kay JM et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80; 1198-1206.
38. Mebazaa A, Martin LD, Robotham JL, Maeda K, Gabrielson EW, Wetzel RC. Right and left ventricular cultured endocardial endothelium produces prostacyclin and PGE2. J. Mol. Cell. Cardiol. 1993; 25; 245-248.
39. Montalescot G, Drobinski G, Meurin P et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am. J. Cardiol. 1998; 82; 749-755.